tag:blogger.com,1999:blog-62778814008843571472012-02-16T01:53:38.268-08:00Mauricio Lema Medina MDnoreply@blogger.comBlogger291100tag:blogger.com,1999:blog-6277881400884357147.post-69857002201949137872009-06-23T13:16:00.000-07:002009-06-23T13:17:33.654-07:00<a href="http://www.esnips.com/doc/90a02522-8835-4644-aae0-5cdb9567ffbd/GCisInBladderCancer2006">GemCis en carcinoma de vejiga avanzado</a><br /><br />- Roberts JT , von der Maase H , Sengeløv L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 17: v118-v122 - 2006.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-6985700220194913787?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-8015486253305350362009-04-09T06:28:00.000-07:002009-04-09T06:35:51.440-07:00<a href="http://www.esnips.com/doc/1c8e5ff2-df12-43cb-8f24-e649714708a3/AdjuvantImatinibGIST">Imatinib adyuvante en GIST</a><br /><br />- Dematteo RP, Ballman KV, Antonescu CR, et al, for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-801548625330535036?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-80488358064412535662009-02-26T08:52:00.000-08:002009-02-26T08:53:51.664-08:00Revisión de la literatura sobre Cáncer anal - <a href="http://www.esnips.com/doc/8fde3944-51b1-4238-ac19-91ccfead610e/CaAnal">Uronis</a><br /><br />- Uronis HE, Bendell JC. Anal Cancer: An Overview. Oncologist 2007 12: 524-534<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-8048835806441253566?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-48252201981531052872009-02-24T08:26:00.001-08:002009-02-24T08:28:15.488-08:00<a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_y9jkl9x1Ivo/SaQgFMlR_FI/AAAAAAAAA-A/bXvd3OSKpzM/s1600-h/OvarioFC.jpg"><img style="cursor:pointer; cursor:hand;width: 400px; height: 324px;" src="http://4.bp.blogspot.com/_y9jkl9x1Ivo/SaQgFMlR_FI/AAAAAAAAA-A/bXvd3OSKpzM/s400/OvarioFC.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5306401534598315090" /></a><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-4825220198153105287?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-84016490675444550502009-02-19T05:52:00.001-08:002009-02-19T05:52:36.547-08:00<span style="font-weight:bold;">Linfoma de Hodgkin</span><br /><br />BEACOPP es superior a AVBD en linfomas de Hodgkin de alto riesgo <a href="http://www.esnips.com/doc/2c7ebfc1-5507-42f1-bbb6-3cc63c3426ed/HD_Beacopp_vs_ABVD">BEACOPP</a><br /><br />- Massimo F, Luminari S, Iannitto E, et al. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009 27: 805-811.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-8401649067544455050?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-62443952134696334462009-02-04T07:00:00.000-08:002009-02-04T07:03:03.935-08:00<span style="font-weight:bold;">Carcinoma de cérvix uterino</span><br />Quimioterapia neoadyuvante para carcinoma de cérvix uterino localmente avanzado de menos de 7 cm de diámetro, seguido por histerectomía radical<br /><br />Paclitaxel + Cisplatino + Ifosfamida neoadyuvante en enfermedad localmente avanzada (Estadíos Ib, IIb de menos de 7 cm), seguida por histerectomía radical - <a href="http://www.esnips.com/doc/db10bfac-875b-4d8b-9c2b-6053454be550/NeoAdjuvantCTinLACervicalCancer">TIP</a><br /><br />- Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study. J Clin Oncol 2002 20: 179-188<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-6244395213469633446?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-14281472643009380812009-01-12T07:06:00.000-08:002009-04-09T06:37:35.750-07:00Terapia adyuvante con Imatinib en GIST - <a href="http://www.esnips.com/doc/1c8e5ff2-df12-43cb-8f24-e649714708a3/AdjuvantImatinibGIST">Imatinib adyuvante en GIST</a><br /><br />- Dematteo RP, Ballman KV, Antonescu CR, et al, for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104<br /><br />Sunitinib en GIST refractario o intolerante a imatinib - <a href="http://www.esnips.com/doc/82c1cc6b-638f-4d43-a061-69c514e78e4b/SUTENT_GIST">Sutent_Refractory_GIST</a><br /><br />- Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 14 ; 368 (9544): 1329-38.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-1428147264300938081?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-2885268452021938482009-01-12T06:57:00.000-08:002009-01-12T08:42:58.150-08:00Los nuevos estándares son cambios al manejo usual de pacientes en diferentes situaciones clínicas. Incluyen: cambios en las recomendaciones terapéuticas, primer enfrentamiento con una situación clínica que exige la adopción de una estrategia con la que no está familiarizado el autor (puede ser realmente nueva, o simplemente de ocurrencia infrecuente), o exposición de nueva evidencia que cambia la práctica - así no tenga utilidad práctica específica. Cuando sea pertinente se establecerá qué artículo previo ya no es considerado relevante para el manejo (o varios artículos). Además de publicarla en estas entradas, se publicarán en la enfermedad específica, en el sitio específico - por eso la búsqueda dentro del BLOG va a originar dos concordancias.<br /><br /><span style="font-weight:bold;">Leucemia mieloide aguda</span><br /><br />CLAG en Leucemia Mieloide Aguda en recaida - <a href="http://www.esnips.com/doc/10b88755-82e5-4122-8ded-a8fa8441e035/CLAG">CLAG_Relapsed_AML</a><br /><br /><a href="http://www.esnips.com/doc/22d12218-9276-4e82-8bdf-3dfd9727c2bc/CLAG">CLAG</a> (En Excel)<br /><br />- Wrzesień-Kuś A, Robak T, Wierzbowska E. et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Annals of Hematology (2005) 84: 557-864.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-288526845202193848?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-24390455643827294532008-11-25T16:42:00.000-08:002008-11-26T11:48:43.327-08:00<span style="font-weight:bold;">1. Linfoma de Hodgkin en recaida</span><br /><br /><a href="http://www.esnips.com/doc/f50d1e08-380d-44e3-8fb6-d3dd00bd908f/BEAM-vs-Dexa-BEAM-in-Relapsed-HD">BEAM vs DexaBEAM</a><br /><br />Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: A randomised trial. Lancet 359:2065-2071, 2002.<br /><br /><a href="http://www.esnips.com/doc/7759b1b5-e23e-4571-abb2-972ac9f1a307/HD">Revisión relevante del ASCO 2004</a><br /><br />Moskowitz CH: Controversies in the management of relapsed and primary refractory Hodgkin´s lymphoma. In American Society of Clinical Oncology Educational Book, 40th Annual Meeting, 2004, pp 360- 367.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-2439045564382729453?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-6925671143974499342008-10-31T19:42:00.000-07:002008-10-31T19:46:36.101-07:00Durante la rotación se discutieron los manejos de las enfermedades neoplásicas encontradas. Las sinopsis se elaboraron en una presentación de power-point: <a href="http://www.esnips.com/doc/6b4aef71-8aa2-4edc-bb79-871674bf7dee/Clinical-Pathways-in-Oncology">SPC</a><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-692567114397449934?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-54402783240820860022008-10-19T17:03:00.000-07:002009-02-04T06:56:48.837-08:00<span style="font-weight:bold;">Enfermedad localmente avanzada</span><br /><br />Paclitaxel + Cisplatino + Ifosfamida neoadyuvante en enfermedad localmente avanzada (Estadíos Ib, IIb de menos de 7 cm), seguida por histerectomía radical - <a href="http://www.esnips.com/doc/db10bfac-875b-4d8b-9c2b-6053454be550/NeoAdjuvantCTinLACervicalCancer">TIP</a><br /><br />- Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study. J Clin Oncol 2002 20: 179-188<br /><br /><span style="font-weight:bold;">Metastásico</span><br /><br />Cisplatino + Topotecán - <a href="http://www.esnips.com/doc/a3ba89d0-2a66-4b38-a2f6-425ab999041f/CisTopotecan_Cervix">CisTopotecán</a><br /><br />- Long HJ, Bundy BN, Grendys E, et al. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005 23: 4626-4633<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-5440278324082086002?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-14827004354785995462008-10-19T10:04:00.000-07:002008-10-19T10:18:14.763-07:00<span style="font-weight:bold;">Metastásico</span><br /><br />Erlotinib + Gemcitabina en primera línea - <a href="http://www.esnips.com/doc/461f4ea0-168f-439d-bc5a-aaf801e5f6af/Erlotinib_PancreaticCa">NCI Canad</a>a<br /><br />- Moore MJ, Goldstein D, Hamm J, et al.Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 25: 1960-1966<br /><br />Gemcitabina es superior a Fluoruracilo - <a href="http://www.esnips.com/doc/999ffbd2-c401-409a-b6e0-c37237e4ffa4/GemcitabineInPancrCa">GemcPancr</a><br /><br />- Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 15: 2403-2413<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-1482700435478599546?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-35025813446541167142008-10-15T18:46:00.000-07:002008-10-15T19:03:20.546-07:00<span style="font-weight:bold;">Malas noticias, cómo transmitirlas con eficacia y sensibilidad</span><br /><br /><a href="http://www.esnips.com/doc/7e33278b-cc13-444f-87b3-5f67b70647d5/SPIKES">SPIKES</a><br /><br /><span style="font-weight:bold;">Setting</span> up the interview (Privacy, please!)<br /><span style="font-weight:bold;">Perception</span> (Before talking, get an idea of what the patient knows)<br /><span style="font-weight:bold;">Invitation</span> (Get an idea of how much information does he or she wants to know)<br /><span style="font-weight:bold;">Knowledge</span> (Give the information, starting with "I have some bad news..." or "I am sorry to inform you that...")<br /><span style="font-weight:bold;">Emotion</span>s (Address the emotion elicited with empathy)<br /><span style="font-weight:bold;">Strategy and Summary</span> (What is the plan. There should always be a plan, even a funeral one will do - just make it explicit!)<br /><br />- Baile WF, Buckman R, Lenzi R, et al. SPIKES--A Six-Step Protocol for Delivering Bad News: Application to the Patient with Cancer. Oncologist 2000 5: 302-311<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-3502581344654116714?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-62472965946689153472008-10-15T17:56:00.000-07:002008-10-15T17:57:50.512-07:00METASTÁSICO<br /><br />Docetaxel + Prednisona en primera línea - <a href="http://www.esnips.com/doc/64163535-c7d3-4cf8-9968-a58a1ad4e40b/TAX-327">TAX 327</a><br /><br />- Tannock IF, de Wit R, Berry WR. et al, the TAX 327 Investigators, Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med 2004 351: 1502-1512<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-6247296594668915347?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-36304714833534301242008-10-14T18:41:00.000-07:002008-10-14T19:18:28.611-07:00TERAPIA ADYUVANTE<br /><br />Interferón alfa adyuvante para melanoma de alto riesgo - <a href="http://www.esnips.com/doc/fb4293a7-b07e-4114-878b-3cab26dd915b/AdjuvantIfnInMelanomaKirkwoodJCO1996">ECOG 1684</a><br />Este el posiblemente el artículo más viejo que continúa vigente.<br /><br />- Kirkwood JM, Strawarderman MH, Ernstoff MS, et al. Interferon alfa 2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7.<br /><br /><br />Peginterferon adyuvante - <a href="http://www.esnips.com/doc/e83ac177-aaaa-4c1b-b17e-a9a6595b4abb/PegIfnMelanoma">EORTC 18991</a><br /><br />- Eggermont AMM, Suciu S, Santinami M, et al. for the EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. The Lancet 2008; 372:117-126<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-3630471483353430124?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-74503506025958373872008-10-14T12:44:00.001-07:002008-10-14T13:45:04.017-07:00<span style="font-weight:bold;">Glioblastoma multiforme</span><br /><br />Quimiorradioterapia con temozolomide - <a href="http://www.esnips.com/doc/1942d93a-bcb1-4218-a692-e0514bb0cb2f/Temozolomide_RT_GBM">NCI Canada</a><br /><br />- Stupp R, Mason WP, van den Bent MJ, et al. the National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005 352: 987-996<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-7450350602595837387?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-55593857508532665122008-10-14T10:12:00.001-07:002010-03-27T05:30:55.509-07:00<span style="font-weight:bold;">No resecable - localmente avanzado</span><br /><br />Cetuximab + Radioterapia - <a href="http://www.esnips.com/doc/6c0d529b-1690-4c67-8bed-6bf9b1bebca7/Cetuximab_RT">Bonner et al.</a><br /><br />- Bonner JA, Harari PM., Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006 354: 567-578<br /><br />Cisplatino + Fluoruracilo + Docetaxel, seguido por radioterapia - <strong>TAX 323</strong><br /><br />Docetaxel 75 mg/m2/día 1, Cisplatino 75 mg/m2/día 1, FU 750 mg/m2/infusión continua de 24 horas, día 1-5. Cada 21 días, por hasta 4 ciclos.<br /><br />- Vermorken JB, Remenar E, van Herpen C et al, the EORTC 24971/TAX 323 Study Group, <br />Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. N Engl J Med 2007 357: 1695-1704 <br /><br /><span style="font-weight:bold;">Refractario o recurrente</span><br /><br />Cisplatino + Cetuximab - <a href="http://www.esnips.com/doc/b076ac6c-2ecd-4ad9-a49e-037b2853d0d4/Extreme">EXTREME</a><br /><br />- Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med 2008 359: 1116-1127<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-5559385750853266512?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-63091454983057376012008-10-13T17:44:00.000-07:002008-10-13T18:55:43.226-07:00<span style="font-weight:bold;">PRIMERA LÍNEA</span><br /><br />Talidomida + Dexametasona como terapia inicial (o de inducción) en mieloma múltiple - <a href="http://www.esnips.com/doc/c485ac8b-2fd3-444a-933f-bf75a8d107dc/ThalDexaInMM">ECOG</a><br /><br />- Rajkumar SV, Blood E, Vesole D, et al. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006 24: 431-436<br /><br /><span style="font-weight:bold;">Autotrasplante en tandem</span><br /><br />Autotrasplante en tándem es superior a trasplante único en mieloma múltiple, especialmente si hay respuesta incompleta con el primer trasplante - <a href="http://www.esnips.com/doc/d41ae504-4fa4-4421-8e06-8195ac0f3a55/IFM">IFM</a><br /><br />- Attal M, Harousseau JL, Facon T, et al, the InterGroupe Francophone du Myelome, Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma. N Engl J Med 2003 349: 2495-2502<br /><br />Talidomida después de autotrasplante - <a href="http://www.esnips.com/doc/9c6e32fc-bf36-4c9b-979b-2db5f5c324fd/ThalAfterHDASCTinMM">ThalPostAutoSCT</a><br /><br />- Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. N Engl J Med 2006 354: 1021-1030<br /><br /><span style="font-weight:bold;">Bortezomib + Melfalán + Prednisona</span><br /><br />Para pacientes que no son candidatos a quimioterapia de altas dosis con trasplante de médula ósea, la combinación Bortezomib + Melfalán + Prednisona es superior - <a href="http://www.esnips.com/doc/d86b9501-ee00-480c-9071-e47597283960/VISTA">VISTA</a><br /><br />- San Miguel, JF, Schlag R, Khuageva, NK, et al, the VISTA Trial Investigators, Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med 2008 359: 906-917<br /><br /><span style="font-weight:bold;">Primera línea en ancianos</span><br /><br />Talidomida + Dexametasona + Melfalán es superior a trasplante en pacientes ancianos con mieloma múltiple - <a href="http://www.esnips.com/doc/3f220765-b9f5-4c9d-b4e9-c6ad67959f84/IFM9906">IFM 99-06</a><br /><br />- Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007; 370: 1209-1218.<br /><br /><span style="font-weight:bold;">SEGUNDA LÍNEA</span><br /><br />Lenalidomida + Dexametasona - <a href="http://www.esnips.com/doc/11bfb73e-dce8-449f-b150-ef226e68b24d/MM010">MM010</a><br /><br />- Dimopoulos M, Spencer A, Attal M, et al, the Multiple Myeloma (010) Study Investigators, Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl J Med 2007 357: 2123-2132<br /><br />Bortezomib en mieloma múltiple en recaida - <a href="http://www.esnips.com/doc/2876d49f-dfbe-4248-ae35-425a5c467484/APEX">APEX</a><br /><br />- Richardson PG, Sonneveld P, Schuster MW, et al, the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators, Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma N Engl J Med 2005 352: 2487-2498<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-6309145498305737601?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-20592512091523586672008-10-13T16:40:00.000-07:002008-10-13T17:25:18.744-07:00<span style="font-weight:bold;">Metastásico</span><br /><br />Sorafenib es superior a la mejor terapia de apoyo en pacientes con carcinoma hepatocelular metastásico - <a href="http://www.esnips.com/doc/a3682bad-1011-4f4e-8ac9-15da12fde11e/Sharp">SHARP</a><br /><br />- Llovet, JM, Ricci S, Mazzaferro V, et al, the SHARP Investigators Study Group, Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008 359: 378-390<br /><br />En el estudio SHARP se incluyeron sólo pacientes con <a href="http://www.esnips.com/doc/546fc1d5-2b78-4066-ab8b-92ec3d7c0552/ChildPughScore">Child-Pugh Score</a> clase A<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-2059251209152358667?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-13588954188601951702008-10-06T09:56:00.000-07:002009-03-19T13:50:24.203-07:00<a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_y9jkl9x1Ivo/SPPbqLE6j4I/AAAAAAAAAe8/JXq9ushRvoo/s1600-h/mRCC_RiskGroupings.jpg"><img style="cursor:pointer; cursor:hand;" src="http://4.bp.blogspot.com/_y9jkl9x1Ivo/SPPbqLE6j4I/AAAAAAAAAe8/JXq9ushRvoo/s400/mRCC_RiskGroupings.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5256786707645894530" /></a><br /><span style="font-weight:bold;">Metastásico</span><br /><br />Categorías de riesgo en carcinoma renal metastásico - <a href="http://www.esnips.com/doc/0a8db5f9-e416-4958-be3f-a8dfe7d2a30e/mRCC_PrognosticGroupings">El Modelo Motzer MSKCC</a><br /><br />- Mekhail TM, Abou-Jawde RM, BouMerhi G, Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. J Clin Oncol 2005 23: 832-841<br /><br /><span style="font-weight:bold;">Tratamientos</span><br />1. <a href="http://www.esnips.com/doc/8c4f6cc6-c064-4c9c-835f-2001442cb592/Avoren">Bevacizumab + Infterferón</a><br /><br />- Escudier B, Pluzanska A, Koralewski P, et al, for the AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet 2007; 370:2103-2111<br /><br />2. Sunitinib es superior al interferón en cáncer renal metastásico - <a href="http://www.esnips.com/doc/77e38a0c-a853-4a6f-832c-a0a8ed5a45bc/SunitinibVsInterferon_mRCC">Sutent in mRCC</a><br /><br />- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med 2007 356: 115-124<br /><br />3. Sorafenib en carcinoma renal metastásico en segunda línea - <a href="http://www.esnips.com/doc/aa839c0c-e27f-478a-9b90-0136174a9f57/Sorafenib_in_2nd_Line_mRCC">TARGET</a><br /><br />- Escudier B, Eisen T, Stadler WM, et al, the TARGET Study Group, Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 2007 356: 125-134<br /><br />4. Temsirolimus en carcinoma renal metastásico de alto riesgo - <a href="http://www.esnips.com/doc/815ed908-9e7d-4927-b05c-35cddd41b641/Temsirolimus_in_HR_mRCC">Global ARCC</a><br /><br />- Hudes G, Carducci M, Tomczak P, et al, the Global ARCC Trial, Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 2007 356: 2271-2281<br /><br />5. Everolimus - <a href="http://www.esnips.com/doc/13654acd-a257-4c1a-bab1-3c974e61d85c/EverolimusRCC">RECORD1</a><br /><br />- Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56.<br /><br />6. Interleucina 2 de altas dosis <a href="http://www.esnips.com/doc/89942746-b057-417d-8d03-4cd1660e189b/IL2inMRCC">IL-2</a><br /><br />- Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1995: 688-696<br /><br /><a href="http://www.esnips.com/doc/6010ee7e-a2df-4b86-a0a3-f6d946d37868/BT09_IL2">Boletín técnico 11 - Altas dosis de Interleucina 2 (.doc, 97, 100 kB)</a><br /><br /><a href="http://www.esnips.com/doc/0d99b568-7815-40b9-b9a5-aa53df818131/guidelines-interleukin-2-for-Safe-administration(2)">Guías para la administración segura de interleucina 2</a><br />- Scwatzentruber D. Guidelines for the safe administration of high-dose interleukin-2. J. Immunother. 2001, 24: 287-293<br /><br /><a href="http://www.esnips.com/doc/7bf5839a-0d1e-4f59-8fc8-903301c1fe55/Guias-para-administrar-en-forma-segura-altas-dosis-de-interleukina-2007">Tabla de administración segura de interleucina 2</a><br /><br /><a href="http://www.esnips.com/doc/63266f38-3061-4f16-b7f3-4f4a742dc113/proleukin">Interleukin 2 - Package insert</a><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-1358895418860195170?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-85499003973154977662008-10-01T12:57:00.000-07:002008-10-01T14:07:22.748-07:00<span style="font-weight:bold;">Leucemia linfoide crónica</span><br /><br />- How I Treat <a href="http://www.esnips.com/doc/6779daed-cab1-41a8-93ff-4c20ca9eb1e6/HITCLL">CLL</a> - Por E. Montserrat<br /><br />- Montserrat E, Moreno C, Esteve J, et al. How I treat refractory CLL. Blood 107: 1276-1283<br /><br /><span style="font-weight:bold;">Leucemia mieloide crónica</span><br /><br />- How I Treat <a href="http://www.esnips.com/doc/67aba77d-77a0-42ff-a836-f8031bbce8d1/HITCML">CML</a> - Por JM Goldman<br /><br />- Goldman JM, How I treat chronic myeloid leukemia in the imatinib era. Blood 110: 2828-2837.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-8549900397315497766?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-34289626625299426472008-10-01T12:56:00.004-07:002009-01-12T06:56:33.917-08:00<span style="font-weight:bold;">Leucemia linfoide aguda</span><br /><br />Hyper-CVAD en Leucemia linfoide aguda - <a href="http://www.esnips.com/doc/4fd95d7a-d232-43b1-ae6d-399f442aa6f3/HiperCVAD">Hyper-CVAD</a><br /><br />- Kantarjian HM, O’Brien S, Smith TL, et al. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. J Clin Oncol 2000 18: 547-561<br /><br />How I Treat <a href="http://www.esnips.com/doc/f4dc1654-55f3-4ba4-89b5-28a774e4293f/HITALL">ALL</a><br /><br />- Rowe JM, Goldstone AH. How I treat acute lymphocytic leukemia in adults Blood 110: 2268-2275<br /><br /><span style="font-weight:bold;">Leucemia / Linfoma tipo Burkitt</span><br /><br />Rituximab + Hyper-CVAD - <a href="http://www.esnips.com/doc/e31b92a7-42b9-45d5-bc9c-6dd3bcaf0a85/R_Hyper_CVAD_Burkitt">R-Hyper-CVAD</a><br /><br />- Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106; 7 - 1569-1580, 2006<br /><br /><span style="font-weight:bold;">Leucemia promielocítica aguda</span><br /><br />Consenso de tratamiento de leucemia promielocítica aguda - <a href="http://www.esnips.com/doc/0e9fc687-6377-4978-a2b2-7c3cefcfa433/PML">PML</a><br /><br />- Sanz MA, Tallman MS, Lo-Coco F. Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia Oncologist 2005 10: 806-814<br /><br /><span style="font-weight:bold;">Leucemia mieloide aguda</span><br /><br />CLAG en Leucemia Mieloide Aguda en recaida - <a href="http://www.esnips.com/doc/10b88755-82e5-4122-8ded-a8fa8441e035/CLAG">CLAG_Relapsed_AML</a><br /><br />- Wrzesień-Kuś A, Robak T, Wierzbowska E. et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Annals of Hematology (2005) 84: 557-864<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-3428962662529942647?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-73407870043978315572008-10-01T12:56:00.003-07:002008-10-11T15:03:07.662-07:00<span style="font-weight:bold;">Quimioterapia perioperatoria (Enfermedad temprana)</span><br /><br />Nomograma de supervivencia luego de cirugía por cáncer gástrico - <a href="http://www.esnips.com/doc/69d98ca3-aef3-48d9-8c17-a2ec62ddc66f/GastricCaNomogram">MSK</a><br /><br />- Kattan MW, Karpeh MS., Mazumdar M, et al. Postoperative Nomogram for Disease-Specific Survival After an R0 Resection for Gastric Carcinoma. J Clin Oncol 2003 21: 3647-3650<br /><br />Quimiorradiación adyuvante (con Folinato + Fluoruracilo) - <a href="http://www.esnips.com/doc/9ff0866d-fd69-4d34-942d-83efc325431f/INT-0116">INT 0116</a><br /><br />- Macdonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730<br /><br />Quimioterapia perioperatoria (con ECF) - <a href="http://www.esnips.com/doc/48e96c10-415b-4cd5-98e9-d7a85f450517/MAGIC">MAGIC</a><br /><br />- Cunningham D, Allum WH, Stenning SP, et al, the MAGIC Trial Participants, Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med 2006 355: 11-20<br /><br /><span style="font-weight:bold;">Quimioterapia en enfermedad avanzada</span><br /><br />Meta-análisis de quimioterapia en cáncer gástrico metastásico - <a href="http://www.esnips.com/doc/f8258178-4de6-4c06-94e9-c70ad5f86f1f/Cochrane_Gastric_Ca">Cochrane</a><br /><br />- Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. The Cochrane Database of Systematic Reviews: Reviews 2005 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD004064.pub2<br /><br />Quimioterapia para enfermedad metastásica (con EOX) - <a href="http://www.esnips.com/doc/20ca2925-ada4-414c-9cd5-b13851a732b3/REAL1">REAL</a> <br /><br />- Cunningham D, Starling N, Rao S, et al, the Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom, Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med 2008 358: 36-46<br /><br />Cisplatino + Paclitaxel para enfermedad metastásica<br />En mi servicio se utiliza el esquema Cisplatino + Paclitaxel como está estipulado en <a href="http://pcgastricca.blogspot.com/">CisPacGaC</a><br /><br />En el ESMO 2008 de Estocolmo tuve la oportunidad de escuchar a D. Cunningham, el más grande experto en carcinoma gástrico del mundo. Resumí su posición sobre el manejo de carcinoma gástrico temprano en mi <a href="http://hemoncblog.blogspot.com/2008/09/notas-del-esmo-de-estocolmo-2008-01.html">blog</a>.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-7340787004397831557?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-85303358829899825452008-10-01T12:56:00.001-07:002008-10-15T18:30:57.804-07:00<span style="font-weight:bold;">CARCINOMA BRONCOGÉNICO DE CÉLULAS NO PEQUEÑAS (NSCLC)</span><br /><br /><span style="font-weight:bold;">QUIMIOTERAPIA EN NSCLC - ADYUVANTE</span><br /><br /><span style="font-weight:bold;">Meta-análisis en quimioterapia adyuvante para carcinoma del pulmón de células no pequeñas</span><br /><br />- <a href="http://www.esnips.com/doc/6d8b80be-fd9e-4594-88ef-303f68d6a088/LACE">LACE Collaboration</a><br /><br />- Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 2008 26: 3552-3559<br /><br />Cisplatino + Vinorelbina para estadíos IB y II - <a href="http://www.esnips.com/doc/8bafcddd-1fcb-4925-895b-a977dafbfaf7/JBR10">JBR.10</a><br /><br />- Winton T, Livingston R, Johnson D, et al, the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators, Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. N Engl J Med 2005 352: 2589-2597<br /><br /><br /><span style="font-weight:bold;">QUIMIOTERAPIA EN NSCLC - PRIMERA LÍNEA</span><br /><br /><span style="font-weight:bold;">Meta-análisis en quimioterapia para carcinoma del pulmón de células no pequeñas avanzado</span><br /><br /><a href="http://www.esnips.com/doc/912a65c5-9f88-468d-b627-ed4f35db757c/NSCLCMA">NSCLC Meta-Análisis</a> - 2008<br /><br />- NSCLC Meta-Analyses Collaborative Group, Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J Clin Oncol 2008 26: 4617-4625<br /><br />"Todas las dupletas basadas en platino son iguales..." - <a href="http://www.esnips.com/doc/dace7594-3c0b-4868-934e-f8f2f8bdcf68/ECOG1594">ECOG 1594</a><br /><br />- Schiller JH, Harrington D, Belani CP, et al, the Eastern Cooperative Oncology Group, Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2002 346: 92-98<br /><br />A lo mejor, Pemetrexed es mejor en adenocarcinoma - <a href="http://www.esnips.com/doc/2485aff9-f65e-4da2-9373-6ced82b32133/Cisplatin_PemetrexedVSCisplatin_Gemcitabine">PemCisTrial</a><br /><br />- Scagliotti GV, Parikh P, von Pawel J, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J. Clin. Oncol. Jul 20, 2008; 26: 3543-3551.<br /><br />Bevacizumab en carcinoma de pulmón de células no pequeñas avanzado - <a href="http://www.esnips.com/doc/40c95d68-cc58-4286-833c-f069f00f459f/E4599">ECOG 4599</a><br /><br />- Sandler A, Gray R, Perry M. et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 2006 355: 2542-2550<br /><br /><span style="font-weight:bold;">QUIMIOTERAPIA EN NSCLC - SEGUNDA LÍNEA</span><br /><br />Docetaxel en segunda línea - <a href="http://www.esnips.com/doc/42bc9eb7-2f42-43e2-b740-012c9d2f6ff2/TAX320">TAX320</a><br /><br />- Fossella FV, DeVore R, Kerr RN, et al. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens. J Clin Oncol 2000 18: 2354-2362<br /><br />Pemetrexed es menos tóxico que el docetaxel en segunda línea - <a href="http://www.esnips.com/doc/0956e4c6-e327-4167-9957-aacd62dababc/PemetrexedVSDocetaxelNSCLC">Pemetrexed</a><br /><br />- Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol 2004 22: 1589-1597<br /><br />Erlotinib en segunda línea - <a href="http://www.esnips.com/doc/3c06b9c5-569b-49ba-8fd2-2fff1d9e3f9b/BR21">BR.21</a><br /><br />- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. the National Cancer Institute of Canada Clinical Trials Group, Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005 353: 123-132<br /><br /><span style="font-weight:bold;">CARCINOMA DEL PULMÓN DE CÉLULAS PEQUEÑAS (SCLC)</span><br /><br />Radioterapia craneal profiláctica en SCLC de estadío extendido - <a href="http://www.esnips.com/doc/636bfe66-78b6-45c1-90d7-befacac0aacb/RT_ES_SCLC">EORTC</a><br /><br />- Slotman B, Faivre-Finn C, Kramer G et al, the EORTC Radiation Oncology Group and Lung Cancer Group, Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. N Engl J Med 2007 357: 664-672<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-8530335882989982545?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-85629450232220432922008-10-01T12:49:00.001-07:002009-04-09T05:44:57.165-07:00<span style="font-weight:bold;">Difuso de células grandes - Fenotipo B (CD20 positivo)</span><br /><br /><span style="font-weight:bold;">Rituximab + CHOP</span><br /><br />Rituximab + CHOP en linfoma difuso de células grandes (En ancianos) - <a href="http://www.esnips.com/doc/0a7dd7cb-24c4-4e41-9e23-a21f2e190624/Rituximab_DLBCL">GELA</a><br /><br />- Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117–4126.<br /><br />Impacto del Rituximab en la supervivencia de <a href="http://www.esnips.com/doc/25c9ef80-9bec-41ce-8319-75c4cea16761/Rituximab_Population_Impact">British Columbia</a><br /><br />- Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027–5233.<br /><br /><span style="font-weight:bold;">Trasplante autólogo "Upfront"</span><br /><br />Trasplante autólogo en primera línea es superior a CHOP en linfomas agresivos - <a href="http://www.esnips.com/doc/761ab9b3-331b-45e6-9f19-4833efd59de2/AutoBMTvsCHOPinAggressiveNHL">GOELAMS</a><br /><br />- Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350:1287–1295<br /><br /><br /><br />How I Treat <a href="http://www.esnips.com/doc/a44de698-a794-4c30-ad87-0353a5c9f154/HITDLBCL">DLBCL</a><br /><br />- James O. Armitage How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110: 29-36<br /><br />Inspirado en ese artículo, y para clarificar mi mente de algunas confusiones, escribí una sinopsis terapéutica suscinta en mi <a href="http://hemoncblog.blogspot.com/2008/04/puntos-sobres-las-es-1-linfoma-difuso.html">blog</a>.<br /><br /><span style="font-weight:bold;">Linfoma de Hodgkin</span><br /><br />BEACOPP es superior a AVBD en linfomas de Hodgkin de alto riesgo <a href="http://www.esnips.com/doc/2c7ebfc1-5507-42f1-bbb6-3cc63c3426ed/HD_Beacopp_vs_ABVD">BEACOPP</a><br /><br />- Massimo F, Luminari S, Iannitto E, et al. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009 27: 805-811<br /><br /><span style="font-weight:bold;">Linfoma Cutáneo de Células T (CTCL) - Sindrome de Sézary (SS)</span><br /><br /><a href="http://www.esnips.com/doc/c2e9db2f-cd00-4381-bf48-0fdd24d510fb/MFSS_ReviewLancet2008">Revisión de CTCL-SS</a>. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008 Mar 15;371(9616):945-57.<br /><br /><a href="http://www.esnips.com/doc/bcc8e782-db09-45ca-9dcf-d7b525cbea1e/VorinostatCTCLLandmarkStudy01">Vorinostat en CTCL en recaida/refractario 01</a>. Duvic M, Talpur R, Ni X et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31–39.<br /><br /><a href="http://www.esnips.com/doc/a58bed34-c9c3-40d9-ba3f-5f3dff18ee87/VorinostatCTCLLandmarkStudy02">Vorinostat en CTCL en recaida/refractario 024</a>. Olsen EA, Kim YH, Kuzel TM et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109–3115<br /><br /><a href="http://www.esnips.com/doc/af9175d3-a5dc-4e54-a9e8-ee314687e317/VorinostatFDAApproval">Vorinostat: Aprobación de la FDA</a>. Mann BS, Johnson JR, Cohen MH, et al. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Oncologist 2007 12: 1247-1252<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-8562945023222043292?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-80806483530639564452008-10-01T12:23:00.001-07:002009-10-13T06:21:28.515-07:00<a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://1.bp.blogspot.com/_y9jkl9x1Ivo/SPVpTjw3ufI/AAAAAAAAAfE/WuAbK72AYig/s1600-h/mCRC1.jpg"><img style="cursor:pointer; cursor:hand;" src="http://1.bp.blogspot.com/_y9jkl9x1Ivo/SPVpTjw3ufI/AAAAAAAAAfE/WuAbK72AYig/s400/mCRC1.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5257223924763572722" /></a><br /><a href="http://www.esnips.com/doc/f877b4ce-8b40-4498-83a9-1f71b9d44cc4/mCRC">Enfoques propios para enfermedad metastásica</a><br /><br />NOVEDAD<br />Cetuximab es ineficaz en cáncer de colon cuando hay mutación del K-ras - <a href="http://www.esnips.com/doc/d64680c0-3f17-4608-8c31-508aa2b79e92/K_Ras_Mutation_And_Cetuximab_mCR">mKras_LOE_Cetuximab</a><br />- Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 2008 359: 1757-1765<br />(23/10/2008)<br /><br />TERAPIA ADYUVANTE<br />Oxaliplatino + Fluoruracilo + Folinato - <a href="http://www.esnips.com/doc/69e6ea3f-caf3-4d13-9210-92f27c9ce4d5/MOSAIC">MOSAIC</a><br /><br />-Andre T, Boni C, Mounedji-Boudiaf L, et al. The Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators, Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med 2004 350: 2343-2351<br /><br />METASTÁSICO<br /><br />IRINOTECÁN Y OXALIPLATINO<br /><br />1. La supervivencia es una función del número de agentes activos recibidos - <a href="http://www.esnips.com/doc/71b3dd2e-4e70-405c-8c2a-05add3086fc6/Grothey2004">Grothey</a><br /><br />- Grothey A, Sargent D, Goldberg RM, et al. Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. J Clin Oncol 2004 22: 1209-1214.<br /><br /><br />2. FOLFOX es superior al IFL - <a href="http://www.esnips.com/doc/e456182d-aa22-43ae-ae2f-e0b919e376f8/GodbergMCRC">N9741</a><br /><br />- Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 1;22(1):23-30.<br /><br />3. La terapia concomitante no es superior a la secuencial - <a href="http://www.esnips.com/doc/2ff1a01e-f076-4b47-8e98-6c8437360352/CAIRO">CAIRO</a><br /><br />Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007 Jul 14;370(9582):135-42. <br /><br />4. La terapia concomitante no es superior a la secuencial - <a href="http://www.esnips.com/doc/80bbe305-2b1e-4fe1-a4b2-a7791cadd423/MRC_FOCUS">FOCUS</a><br /><br />- Seymour MT, Maughan TS, Ledermann JA, et al; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007 Jul 14;370(9582):143-52. <br /><br />5. Inducción con oxaliplatino, seguido por descanso, seguido por reinducción - <a href="http://www.esnips.com/doc/485b2bf3-5553-4f3f-8899-6373657b343d/Optimox1">OPTIMOX1</a><br /><br />- Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer--A GERCOR Study. J Clin Oncol 2006 24: 394-400<br /><br />6. FOLFOX seguido por FOLFIRI o viceversa son equivalentes - <a href="http://www.esnips.com/doc/7298b43d-6011-4345-a893-478c825f2410/FOLFOX_FOLFIRI_o_Al_Revés">GERCOR</a><br /><br />- Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237, 2004<br /><br />BEVACIZUMAB<br /><a href="http://3.bp.blogspot.com/_y9jkl9x1Ivo/StR-rzEhIFI/AAAAAAAABp8/3SsRQ-88QRQ/s1600-h/mCRCBevCet.jpg"><img style="cursor:pointer; cursor:hand;width: 400px; height: 251px;" src="http://3.bp.blogspot.com/_y9jkl9x1Ivo/StR-rzEhIFI/AAAAAAAABp8/3SsRQ-88QRQ/s400/mCRCBevCet.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5392073944777957458" /></a><br />Fecha: 10/2009<br /><br />1. IFL + BEVACIZUMAB EN PRIMERA LÍNEA - <a href="http://www.esnips.com/doc/400455e6-39e8-48ad-bc59-1396e2f3c8e7/Bev_IFL_mCRC">IFL-BeV</a><br /><br />- Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004 350: 2335-2342<br /><br />2. FOLFIRI + BEVACIZUMAB - <a href="http://www.esnips.com/doc/40e5849b-29f3-430c-a72f-452f5b681bd8/PACCE01">PACCE</a><br /><br />- Hecht JR, Mitchell E, Chidiac T, et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. J Clin Oncol 2009 27: 672-680.<br /><br /><br />Paulo Hoff del Hospital Sirio Libanés de Sao Paulo impartió una charla bastante educativa que la resumí en mi <a href="http://hemoncblog.blogspot.com/2008/03/bevacizumab-preceptorship-1.html">blog</a>. También fue educativa la sesión educativa del ESMO 2008 en Estocolmo sobre <a href="http://hemoncblog.blogspot.com/2008/09/notas-del-esmo-de-estocolmo-2008-02.html">terapia secuencial versus combinada</a> en cáncer de colon y recto metastásico.<br /><br />Altamente relevante para el uso del Cetuximab en cáncer colorrectal, está el análisis de subgrupo del CRYSTAL en el que se estableció que este agente sólo funciona en pacientes que tienen K-RAS no mutado (<a href="http://hemoncblog.blogspot.com/2008/09/notas-del-esmo-de-estocolmo-2008-05.html">ESMO Oncology Highlights - 2008 - punto 3</a>)<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-8080648353063956445?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-40187582995916888862008-10-01T10:57:00.000-07:002008-10-15T18:39:08.317-07:001. Guías de la <a href="http://www.esnips.com/doc/69143bbd-9131-494b-a2ef-b5eef99b9193/MBC_ESMO">ESMO</a><br /><br />2. <a href="http://www.esnips.com/doc/ecfa7273-39e1-45d0-8ee7-39af2ff209a2/MBC_MLM_2008">Visión personal</a><br /><br /><span style="font-weight:bold;">Ensayos Clínicos Relevantes</span><br /><br /><span style="font-weight:bold;">Quimioterapia</span><br /><br />1. Quimioterapia secuencial versus concomitante - <a href="http://www.esnips.com/doc/4bfa5086-bc62-4cdc-b372-82042b7a5a5e/E1193">E1193</a><br /><br />- Sledge GW, Neuberg D, Bernardo P, et al. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). J Clin Oncol 2003 21: 588-592<br /><br />2. Adición de Bevacizumab a quimioterapia - <a href="http://www.esnips.com/doc/4b0577ed-3fbc-47dd-b1d9-e0ad70021d2c/E2100">E2100</a><br /><br />- Miller K, Wang M, Gralow J, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 2007 357: 2666-2676<br /><br />3. Docetaxel + Capecitabina en primera línea<br /><br />- <a href="http://www.esnips.com/doc/72cafde8-eb52-4858-ad50-219bb1c34f86/DocCapeMBC">O'Shaughnessy J</a>, Miles D, Vukelja S, et al. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. J Clin Oncol 2002 20: 2812-2823<br /><br />4. Gemcitabina + Paclitaxel en primera línea - <a href="http://www.esnips.com/doc/754e8735-8eb6-44fa-86e8-355bb265e2cc/PacGemInMBC">GemPacMBC</a><br /><br />- Albain KS, Nag SN, Calderillo-Ruiz G, et al. Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment. J. Clin. Oncol. Aug 20, 2008; 26: 3950-3957<br /><br /><span style="font-weight:bold;">Anti HER2</span><br /><br />1. Pivotal trial en HER2 positivo - primera línea<br /><br />- <a href="http://www.esnips.com/doc/f28a76d5-e303-4912-abef-9efda50f81ec/HER2_PivotalTrial">Slamon DJ</a>, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 2001 344: 783-792<br /><br />2. Lapatinib + Capecitabina<br /><br />- <a href="http://www.esnips.com/doc/2ed11a0e-2eb1-4437-91bc-8c8b1ec3348b/Lapatinib">Geyer CE</a>, Forster J, Lindquist D et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2006 355: 2733-2743<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-4018758299591688886?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-59136713635294877252008-09-21T20:01:00.000-07:002009-01-14T10:44:45.616-08:001. Guías de la <a href="http://www.nccn.org/">NCCN</a> (National Comprehensive Cancer Network). <br /><br />2. Guías de la <a href="http://www.esmo.org/home.html">ESMO</a> (European Society for Medical Oncology). Estas son particularmente relevantes para este grupo de pacientes. <br /><br />- <a href="http://annonc.oxfordjournals.org/cgi/reprint/19/suppl_2/ii7">B. Pestalozzi</a> , M. Castiglione , and On behalf of the ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology Advance Access published on May 1, 2008, DOI 10.1093/annonc/mdn071. Ann Oncol 19: ii7-ii10<br /><br />3. Consenso de St. Gallen 2007: Cada 2 años se reunen los expertos más importantes de la mastología mundial en este pueblito de Suiza para establecer el consenso de tratamiento de cáncer de mama temprano. Las recomendaciones de San Galo influyen en el manejo de los oncólogos en Europa y en Colombia. Yo no las sigo estrictamente.<br /><br />- <a href="http://annonc.oxfordjournals.org/cgi/reprint/18/7/1133">A. Goldhirsch</a> , W. C. Wood , R. D. Gelber , A. S. Coates , B. Thürlimann , H. -J. Senn , and Panel Members. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18: 1133-1144.<br /><br />4. Meta-análisis de quimioterapia para carcinoma de mama temprano (Oxford overview)<br /><br />- <a href="http://www.esnips.com/doc/74378797-f7fe-4131-9181-35b00c2a95a6/EBCTCG">Early Breast Cancer Trialists' Collaborative Group (EBCTCG</a>). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 2005; 365:1687-1717<br /><br />5. <a href="http://www.adjuvantonline.com/">Adjuvant</a> online: Es un calculador para establecer los riesgos de recidiva tumoral, con las diferentes estrategias de tratamiento en mujeres con carcinoma de mama temprano de 35 a 69 años de edad.<br /><br /><span style="font-weight:bold;">Inhibidores de aromatasa adyuvantes</span><br /><br /><span style="font-weight:bold;">A. Upfront</span><br />1. Anastrozol - <a href="http://www.esnips.com/doc/0d3377f1-d806-4348-bfcb-45c76e7e8a5e/ATAC-100">ATAC 100</a> -<br /><br />- Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 Jan;9(1):45-53<br /><br />2. Letrozol - <a href="http://www.esnips.com/doc/d67f43c0-d908-439c-8355-391d92ab7a62/Big198">BIG 1.98</a><br /><br />- The Breast International Group (BIG) 1-98 Collaborative Group, A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. N Engl J Med 2005 353: 2747-2757<br /><br /><span style="font-weight:bold;">B. Switch</span><br />1. Exemestano - <a href="http://www.esnips.com/doc/e2870ba2-50fa-482a-8295-1db0074d8792/IES">IES</a><br /><br />-Coombes RC, Hall E, Gibson LJ, et al, the Intergroup Exemestane Study, A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. N Engl J Med 2004 350: 1081-1092<br /><br />2. Anastrozol - <a href="http://www.esnips.com/doc/c516244c-45d4-414c-a539-bdb7b4b6ba9a/ARNO95">ARNO-95</a><br /><br />- Kaufmann M, Jonat W, Hilfrich J, et al. Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study. J Clin Oncol 2007 25: 2664-2670<br /><br /><span style="font-weight:bold;">C. Adyuvancia extendida</span><br />1. Letrozol - <a href="http://www.esnips.com/doc/b997b768-be8d-45a5-a694-a7f11d3f5ce5/MA17">MA17</a><br /><br />- Goss PE, Ingle JN, Martino S, et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. N Engl J Med 2003 349: 1793-1802<br /><br /><span style="font-weight:bold;">HER2 Positivo</span><br />1. Trastuzumab - <a href="http://www.esnips.com/doc/8aa08f20-8a7b-4433-81fd-bd8bd2f8715c/HERA">HERA</a> -<br /><br />- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al, the Herceptin Adjuvant (HERA) Trial Study Team, Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005 353: 1659-1672.<br /><br />2. Trastuzumab neoadyuvante - <a href="http://www.esnips.com/doc/94bc7916-7805-470f-b1d1-0191e7a73006/Neoadjuvant_Paclitaxel_FEC_Trastuzumab_HER2">MD Anderson</a><br /><br />- Buzdar AU, Valero V, Ibrahim N, et al. Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clin Cancer Res 2007 13: 228-233<br /><br /><span style="font-weight:bold;">Quimioterapia</span><br /><br />1. Dosis densas - <a href="http://www.esnips.com/doc/a8501a3f-7c97-4ccb-83c0-f34ffcef750b/DoseDense">ATC</a><br /><br />- Citron ML, Berry DA., Cirrincione C, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003 21: 1431-1439.<br /><br />2. Docetaxel + Ciclofosfamida - <a href="http://www.esnips.com/doc/6e4a3cd2-bbaf-4e0d-b16a-6c7fe502124f/TC">TC</a><br /><br />- Jones SE, Savin MA, Holmes FA, et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. J Clin Oncol 2006 24: 5381-5387<br /><br />3. Antraciclinas seguida por paclitaxel - <a href="http://www.esnips.com/doc/23801f9d-4f68-49ec-ae45-72344a99de28/CALGB9344">CALGB 9344</a><br /><br />- Henderson IC, Berry DA, Demetri GD, et al. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. J Clin Oncol 2003 21: 976-983<br /><br />4. CEF vs CMF - <a href="http://www.esnips.com/doc/64c11e5d-ccbd-4a33-8979-5323e3cb76bf/BC_CEF_CMF_2006">NEAT</a>. <br /><br />Poole CJ, Earl HM, Hiller L, et al., the NEAT Investigators and the SCTBG, Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. N Engl J Med 2006 355: 1851-1862<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-5913671363529487725?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0tag:blogger.com,1999:blog-6277881400884357147.post-75962260362787063862008-09-21T19:53:00.000-07:002009-04-09T06:48:32.052-07:00La oncología clínica es una ciencia dinámica. Este blog es creado para una rotación específica de octubre de 2008. El objetivo de la rotación es familiarizar a la estudiante con la práctica usual de esta disciplina en Colombia. Para tal fin, se aglutinan en este blog documentos, enlaces y otros productos que se refieren a las causas de consulta más comunes en la práctica del autor:<br /><br />1. <a href="http://mlmoncorotation.blogspot.com/2008/09/cncer-de-mama-temprano.html">Cáncer de mama temprano</a><br />2. <a href="http://mlmoncorotation.blogspot.com/2008/10/cncer-de-mama-metastsico.html">Cáncer de mama metastásico</a><br />3. <a href="http://mlmoncorotation.blogspot.com/2008/10/cncer-de-colon-y-recto.html">Cáncer de colon y recto</a><br />4. <a href="http://mlmoncorotation.blogspot.com/2008/10/linfomas-y-entidades-afines.html">Linfomas y entidades afines</a><br />5. <a href="http://mlmoncorotation.blogspot.com/2008/10/cncer-del-pulmn.html">Cáncer del pulmón</a><br />6. <a href="http://mlmoncorotation.blogspot.com/2008/10/cncer-gstrico.html">Cáncer gástrico</a><br />7. <a href="http://mlmoncorotation.blogspot.com/2008/10/leucemias-agudas.html">Leucemias agudas</a><br />8. <a href="http://mlmoncorotation.blogspot.com/2008/10/leucemias-crnicas.html">Leucemias crónicas</a><br />9. <a href="http://mlmoncorotation.blogspot.com/2009/02/cancer-de-ovario.html">Cáncer de ovario</a><br />10. <a href="http://mlmoncorotation.blogspot.com/2008/10/carcinoma-renal.html">Carcinoma de células renales</a><br />11. <a href="http://mlmoncorotation.blogspot.com/2008/10/cncer-de-crvix-uterino.html">Cáncer del cérvix uterino</a><br />12. Cáncer de primario desconocido<br />13. <a href="http://mlmoncorotation.blogspot.com/2008/10/gliomas.html">Gliomas</a><br />14. <a href="http://mlmoncorotation.blogspot.com/2008/10/carcinoma-hepatocelular.html">Cáncer hepatocelular</a><br />15. <a href="http://mlmoncorotation.blogspot.com/2008/10/mieloma-mltiple.html">Mieloma múltiple</a><br />16. <a href="http://mlmoncorotation.blogspot.com/2008/10/carcinoma-de-cabeza-y-cuello.html">Carcinoma de cabeza y cuello</a><br />17. <a href="http://mlmoncorotation.blogspot.com/2008/10/cncer-de-prstata.html">Carcinoma de próstata</a><br />19. <a href="http://mlmoncorotation.blogspot.com/2009/02/carcinoma-anal.html">Carcinoma de ano</a><br />20. <a href="http://mlmoncorotation.blogspot.com/2009/01/gist.html">GIST - Tumores Estromales Gastrointestinales</a><br /><br /><span style="font-weight:bold;">Guías de tratamiento</span><br />Los organismos internacionales más importantes elaboran guías de manejo para los tumores más comunes. A continuación se enumeran las 3 principales:<br /><br />1. Guías de la <a href="http://www.nccn.org/">NCCN</a> (National Comprehensive Cancer Network).<br />Las guías de la NCCN son elaboradas por los centros de excelencia norteamericanos. Son las más utilizadas en los Estados Unidos. En gran medida, son las que sigo en mi práctica diaria - las prefiero a todas las demás.<br /><br />2. Guías de la <a href="http://www.esmo.org/home.html">ESMO</a> (European Society for Medical Oncology).<br />Las guías de la ESMO son cortas y relevantes. Son un poco más conservadoras que la NCCN, pero son también adecuadas.<br /><br />3. Guías de la <a href="http://www.cancer.gov/cancer_information/">NCI</a> (National Cancer Institute, de los Estados Unidos). <br />Estas guías son especialmente populares entre los pacientes y los médicos no oncólogos. Están bien elaboradas, pero son menos detalladas que las dos previas.<br /><br />4. Para comparación de los criterios de estadificación TNM: <a href="http://www.yourfilelink.com/get.php?fid=476029">AJCC del TNM - versiones 5 y 6</a><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6277881400884357147-7596226036278706386?l=mlmoncorotation.blogspot.com' alt='' /></div>Mauricio Lema Medina MDnoreply@blogger.com0